SeminarProstate cancer
Introduction
Prostate cancer is a major health issue, with approximately 1·3 million new cases diagnosed worldwide every year. About 10 million men are presently living with a diagnosis of prostate cancer, and approximately 700 000 of these are living with metastatic disease.1, 2 Metastatic prostate cancer accounts for more than 400 000 deaths annually, and this mortality is expected to more than double by 2040. A similar number of men are estimated to be living with treatment-related morbidity for more than 10 years after diagnosis.1, 2
Since the publication of the previous Seminar,3 research efforts have continued to expand our understanding of prostate cancer. Insights into initial development and underlying biology, the ability to diagnose primary and metastatic cancer, and treatment options have developed greatly. This Seminar will focus on the latest developments, how they relate to previous data, and their clinical implications, and should be read in the context of the wide variation in health-care resources available to patients with prostate cancer globally.4
Section snippets
The biology of prostate cancer
The oncogenesis of prostate cancer is associated with complex interactions between inherent germline susceptibility, acquired somatic gene alterations, and microenvironmental and macroenvironmental factors. Localised prostate cancer often contains multiple foci containing different genetic alterations with different capacity for metastatic seeding and inherent treatment resistance.
The adult human prostate is structurally divided into central, transition, and peripheral zones. The outermost
Prostate-specific antigen screening
Prostate-specific antigen (PSA) screening generally refers to an organised programme or policy under which men, usually between the ages of 50 years and 75 years, are invited to take a PSA test and potentially a digital rectal examination as part of a surveillance strategy to detect prostate cancer. This approach contrasts with an early-detection programme under which men can request a PSA test after discussion with their primary health-care provider, which is not widely offered worldwide. At
Management of primary prostate cancer
The intensity of treatment offered for the intrapelvic component of prostate cancer is based on key clinicopathological factors, including PSA concentrations, clinical tumour stage, and histological grade, in accordance with the reclassification of the Gleason score to the International Society of Urological Pathology Grade Group classification.64 The standard division into low-risk, intermediate-risk, and high-risk prostate cancer increasingly incorporates factors such as number of positive
Oligometastatic prostate cancer
The oligometastatic state is typically defined as prostate cancer with three to five metastatic lesions,99 and can be further subdivided by the interval between the appearance of deposits.100 Interest has surged in metastasis-directed therapy for oligometastatic disease with more sensitive molecular imaging, which reclassifies non-metastatic disease on conventional imaging to metastatic disease. Three randomised phase 2 trials (table 3) have shown that metastasis-directed therapy might prolong
Metastatic castration-sensitive prostate cancer
Although early detection and improved local treatments have resulted in a reduction in mortality, 20–40% of patients will develop recurrence (figure 2). Patients who present with metastatic disease at initial presentation typically have cancers with a more aggressive biology and have a shorter overall survival compared with patients who develop metastatic recurrence years after the initial diagnosis of primary prostate cancer.105, 106
Reduction of circulating testosterone via chemical or
Non-metastatic castration-resistant prostate cancer
Non-metastatic CRPC (nmCRPC) is defined by rising PSA and castrate levels of serum testosterone and no evidence of metastatic disease on conventional imaging (bone scintigraphy and CT scan), and is a consequence of androgen deprivation therapy being used at the time of biochemical relapse after definitive therapy for localised prostate cancer. Patients with nmCRPC are often asymptomatic and have variable PSA doubling times and life expectancy. Clinical interest in nmCRPC has been driven by
AR-targeted therapy
Novel AR-targeted therapies for the treatment of mCRPC are well established. The phase 3 COU-AA-301121, 124 and COU-AA-302119, 125 trials showed an approximate 4 month survival advantage with abiraterone plus prednisone over placebo in both the pre-docetaxel and post-docetaxel disease state (table 5). Abiraterone also improved quality of life, pain control, and reduced skeletal-related events. The potent AR antagonist enzalutamide, which impairs AR nuclear translocation and binding to androgen
Conclusion
Enormous advances in the understanding of the biology of prostate cancer, imaging technology, and therapeutic approaches have been made in the last decade. The debate over PSA-based prostate cancer screening has benefited from the maturation of several large randomised controlled trials that have inspired a risk-based screening approach that, combined with MRI, can safely avoid a substantial number of biopsies. Similarly, the initial characterisation of prostate cancer after diagnosis has
Declarations of interests
SGW reports grant support from Bristol-Myers Squibb; consultancy fees and travel support from Astellas Pharma, Janssen, Bayer, Amgen, and Noxopharm paid to institution; and chaired the prostate cancer subcommittee of the Australia and New Zealand Urogenital and Prostate clinical trials group, during which time he received scientific grant support from Bayer and Astellas Pharma. SS reports advisory board fees paid to institution and grant support from AstraZeneca, Merck Sharp & Dohme, Amgen,
References (161)
- et al.
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
Lancet
(2018) - et al.
Prostate cancer
Lancet
(2016) - et al.
Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013
Lancet Oncol
(2013) - et al.
Cell types of origin for prostate cancer
Curr Opin Cell Biol
(2015) - et al.
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
Lancet Oncol
(2014) - et al.
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
Cancer Cell
(2011) - et al.
Genomic hallmarks and structural variation in metastatic prostate cancer
Cell
(2018) - et al.
Integrative clinical genomics of advanced prostate cancer
Cell
(2015) - et al.
Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress
Cell Rep
(2020) - et al.
A 16-yr follow-up of the European randomized study of screening for prostate cancer
Eur Urol
(2019)
Prostate imaging reporting and data system version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2
Eur Urol
PI-RADS Prostate Imaging—Reporting and Data System: 2015, version 2
Eur Urol
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
Lancet
Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study
Lancet Oncol
Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study
Eur Urol
Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis
Eur Urol
Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: a cost-effectiveness analysis based on the Prostate MR Imaging Study (PROMIS)
Eur Urol
Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology position in 2019
Eur Urol
Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis
Eur Urol
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Lancet Oncol
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Lancet
Is prostate-specific membrane antigen positron emission tomography/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA Trial
Eur Urol
A contemporary prostate cancer grading system: a validated alternative to the Gleason score
Eur Urol
Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort
Eur Urol
Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations—a report of a European School of Oncology Task Force
Eur Urol
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Lancet
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
Lancet
Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials
Int J Radiat Oncol Biol Phys
Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials
Cancer Treat Rev
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer
Int J Radiat Oncol Biol Phys
Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR Trial
Int J Radiat Oncol Biol Phys
Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study
Lancet
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Lancet
Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial
Eur Urol
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial
Eur Urol
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
Lancet
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial
J Urol
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Lancet
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
Lancet Oncol
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
Lancet Oncol
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Lancet
Novel insights into the management of oligometastatic prostate cancer: a comprehensive review
Eur Urol Oncol
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Lancet Oncol
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
Lancet
Prostate cancer
Nat Rev Dis Primers
Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay
Proc Natl Acad Sci USA
The inflammatory microenvironment and microbiome in prostate cancer development
Nat Rev Urol
TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer
Clin Cancer Res
Genomic hallmarks of localized, non-indolent prostate cancer
Nature
The molecular taxonomy of primary prostate cancer
Cell
Cited by (236)
Non-Invasive Diagnosis of Prostate Cancer and High-Grade Prostate Cancer Using Multiparametric Ultrasonography and Serological Examination
2024, Ultrasound in Medicine and BiologyManagement of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey
2024, Actas Urologicas EspanolasNovel estrogen receptor β/histone deacetylase dual-targeted near-infrared fluorescent probes as theranostic agents for imaging and treatment of prostate cancer
2024, European Journal of Medicinal Chemistry